This randomised, double-blind, multicentre trial will evaluate the immunogenicity and safety of three consecutive vaccine lots of the freeze-dried formulation of MVA-BN
smallpox vaccine, similar to the prior completed phase 3 study for the liquid-frozen MVA-BN formulation.
It reported: "After the confirmation on Friday, September 7 of the first case of human monkeypox in England, Public Health England (PHE), as part of their response, engaged Bavarian Nordic to assist in the supply of its IMVANEX(r)
smallpox vaccine, which is approved in the European Union.
the research suggested that the
smallpox vaccine might actually have come from horses, not cows, which would mean we should perhaps be talking about 'equination' and 'equines'.
Similarly, persons administering ACAM2000
smallpox vaccine to laboratory and health care personnel at risk for occupational exposure to orthopoxviruses can decrease the risk for inadvertent infection through recommended infection prevention measures.
More research on the immunogenicity of
smallpox vaccine is needed but is challenged by the absence of smallpox disease to test the efficacy of vaccination.
If you're not concerned about the
smallpox vaccine, what about the swine flu vaccine ...
Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation
smallpox vaccine, IMVAMUNE(R).
Bavarian Nordic has ongoing contracts with the United States government for the late-stage development and procurement of the company's third-generation
smallpox vaccine, IMVAMUNE.
Allen, a journalist, tells the story from the turn of the 20th century and the development of the
smallpox vaccine. He describes the wartime governmental campaigns to protect children against the ravages of typhoid fever, diphtheria, and yellow fever and explains the legendary rivalry between Jonas Salk and Albert Sabin and their respective polio vaccines.
PREP also directs the secretary of the Department of Health and Human Services to develop a compensation program for victims similar to the one now in use for
smallpox vaccine.
Shares in Acambis, who are best known for developing the
smallpox vaccine ACAM2000, rose three per cent yesterday